The first trial results of the Ebola vaccine at Oxford University show that it has an acceptable safety profile and is generating the desirable immune response. The vaccine, against the Zaire strain of Ebola, can now be tested in West Africa. The vaccine was co-developed by US' National Institute of Health and GlaxoSmithKline.